Seelos Therapeutics Total Assets 2006-2021 | SEEL

Seelos Therapeutics total assets from 2006 to 2021. Total assets can be defined as the sum of all assets on a company's balance sheet.
Seelos Therapeutics Annual Total Assets
(Millions of US $)
2020 $17
2019 $11
2018 $0
2017 $7
2016 $5
2015 $8
2014 $15
2013 $23
2012 $24
2011 $17
2010 $19
2009 $21
2008 $9
2007 $11
2006 $20
2005 $13
Seelos Therapeutics Quarterly Total Assets
(Millions of US $)
2021-09-30 $81
2021-06-30 $90
2021-03-31 $41
2020-12-31 $17
2020-09-30 $10
2020-06-30 $8
2020-03-31 $14
2019-12-31 $11
2019-09-30 $16
2019-06-30 $10
2019-03-31 $12
2018-12-31 $0
2018-09-30 $6
2018-06-30 $7
2018-03-31 $6
2017-12-31 $7
2017-09-30 $9
2017-06-30 $9
2017-03-31 $5
2016-12-31 $5
2016-09-30 $8
2016-06-30 $6
2016-03-31 $10
2015-12-31 $8
2015-09-30 $10
2015-06-30 $11
2015-03-31 $20
2014-12-31 $15
2014-09-30 $20
2014-06-30 $20
2014-03-31 $25
2013-12-31 $23
2013-09-30 $22
2013-06-30 $27
2013-03-31 $17
2012-12-31 $24
2012-09-30 $41
2012-06-30 $29
2012-03-31 $32
2011-12-31 $17
2011-09-30 $14
2011-06-30 $14
2011-03-31 $20
2010-12-31 $19
2010-09-30 $0
2010-06-30 $24
2010-03-31 $22
2009-12-31 $21
2009-09-30 $7
2009-06-30 $8
2009-03-31 $9
2008-12-31 $9
2008-09-30 $8
2008-06-30 $11
2008-03-31 $9
2007-12-31 $11
2007-09-30 $11
2007-06-30 $13
2007-03-31 $18
2006-12-31 $20
2006-09-30 $14
2006-06-30 $16
2006-03-31 $18
2005-12-31 $13
2005-09-30 $17
2005-06-30 $15
2005-03-31 $15
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.121B $0.000B
Seelos Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focused on the development and advancement of novel therapeutics to address unmet medical needs for central nervous system disorders. The company's product pipeline consists of SLS-002, SLS-006, SLS-008, SLS-010 and SLS-012 which are in clinical stage. Seelos Therapeutics Inc., formerly known as Apricus Biosciences Inc., is based in New York, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $141.036B 8.91
Bio-Rad Laboratories (BIO.B) United States $17.472B 35.46
QIAGEN (QGEN) Netherlands $11.101B 18.80
Biohaven Pharmaceutical Holding (BHVN) United States $7.210B 0.00
Emergent Biosolutions (EBS) United States $2.527B 9.09
Arcus Biosciences (RCUS) United States $2.184B 0.00
Myovant Sciences (MYOV) United Kingdom $1.260B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.080B 0.00
Zymeworks (ZYME) Canada $0.522B 0.00
SQZ Biotechnologies (SQZ) United States $0.201B 0.00
Ambrx Biopharma (AMAM) United States $0.191B 0.00
Enzo Biochem (ENZ) United States $0.154B 19.81